Evaluation of an oral direct anti-Xa anticoagulant, apixaban, for the prevention of venous thromboembolism in patients with myeloma treated with IMiD* compounds: A pilot study (MYELAXAT).
B. Pégourie, G. Pernod
Evaluation of an oral direct anti-Xa anticoagulant, apixaban, for the prevention of venous thromboembolism in patients with myeloma treated with IMiD* compounds: A pilot study (MYELAXAT). - 2017 - 8019-8019
Serial 7158680 35 https://doi.org/10.1200/JCO.2017.35.15_suppl.8019 Document_7158680_42549.pdf
0732183X
Evaluation of an oral direct anti-Xa anticoagulant, apixaban, for the prevention of venous thromboembolism in patients with myeloma treated with IMiD* compounds: A pilot study (MYELAXAT). - 2017 - 8019-8019
Serial 7158680 35 https://doi.org/10.1200/JCO.2017.35.15_suppl.8019 Document_7158680_42549.pdf
0732183X